Dr. Jonathan Halperin Profile
Dr. Raymond Wong Profile

Panel Discussion - Part 4

6. Please comment on a case of a male patient with acute coronary syndrome, who developed stent thrombosis on the evening of discharge. He had a platelet count of 576,000 and was treated with low molecular Readmore >>
weight heparin and antiplatelet agents. But on day 2, his platelet count kept dropping from 300,000 to 270,000 and then 33,000. Low molecular weight heparin was withdrawn and he was switched to dual antiplatelet therapy and fondaparinux. The patient also developed acute limb ischemia following intra-aortic balloon pump (IABP) therapy.

6. 급성 관상 동맥 증후군을 가지고 있으며 퇴원한 저녁에 스텐트 혈전증이 발생한 남성 환자 사례에 대해 의견을 제시 해 주십시오. 그의 혈소판 수는 576,000개 였으며 저 분자량 헤파린과 항 혈소판제로 치료를 받고 Readmore >>
있었습니다. 그러나 제2일에 그의 혈소판 수는 300,000개에서 270,000개로 그리고 다시 33,000개로 계속 떨어졌습니다. 저 분자량 헤파린 치료가 철회되고 그는 이중 항 혈소판 요법 및 폰다파리눅스 치료로 전환되었습니다. 또한 대동맥내 풍선 펌프(IABP) 치료 후 환자에게 급성 사지 허혈이 발생하였습니다.

6. Hãy đưa ra ý kiến về trường hợp một bệnh nhân nam bị hội chứng mạch vành cấp tính, người đã bị huyết khối stent khi xuất viện. Ông có lượng tiểu cầu là 576.000 và được điều trị với heparin phân tử Readmore >>
thấp và các thuốc kháng tiểu cầu. Nhưng ở ngày thứ 2, lượng tiểu cầu của ông giảm từ 300.000 xuống 270.000 và sau đó là 33.000. Heparin khối lượng phân tử thấp được thu hồi và ông được chuyển sang điều trị bằng thuốc kháng tiểu cầu kép và fondaparinux. Bệnh nhân cũng bị thiếu máu chi cấp tính sau khi điều trị bơm bóng nội động mạch chủ (IABP).

6. Silakan berkomentar pada kasus pasien laki-laki dewasa dengan sindrom koroner akut, yang mengalami stent trombosis pada malam pelepasan. Ia memiliki jumlah platelet sebesar 576.000 dan dirawat dengan Readmore >>
low molecular weight heparin dan agen antiplatelet. Namun pada hari 2, jumlah plateletnya terus menurun dari 300.000 ke 270.000 dan kemudian menjadi 33.000. Low molecular weight heparin tidak digunakan lagi dan perawatannya diganti ke terapi antiplatelet dual dan fondaparinux. Pasien juga mengalami iskemik anggota tubuh akut diserta terapi intra-aortic ballon pump (IABP).

Subtitles

For Healthcare Professional Use ONLY

X

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, USA

Jonathan Halperin is the Robert and Harriet Heibrunn Professor of Medicine at The Mount Sinai School of Medicine, New York University and Director of Clinical Cardiology in the Zena and Michael A. Wierner Cardiovascular Institute at The Mount Sinai Medical Center.

Professor Halperin was awarded an MD from Boston University in 1975. He has previously served in various federal appointments which included the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration and the National Institutes of Health where he was in the Data Safety Monitoring board for the clinical trial of aspirin and simvastatin in pulmonary arterial hypertension and in the clinical trial coordinating centre of the National Institutes of Health. He was the principal cardiologist who spearheaded the SPAF (Stroke Prevention in Atrial Fibrillation clinical trials). The trials were conducted in multiple centres where 3,600 patients and more than 100 investigators were involved. Currently, he is involved in several clinical trials with the objective of developing more effective drugs for the prevention of ischemia in a range of cardiovascular disease conditions.

Professor Halperin has authored a wide range of materials including over 100 peer-reviewed reports, books, chapters, guidelines and position statements, invited articles and reviews, clinical case reports, and abstracts. His numerous awards and honours include the Champion of Heart and Stroke, Master of the Society for Vascular Medicine, The Heart of New York Award, The Heart of New York Presidential Salute, Howard B. Sprague Research Fellowship Award, Samuel Bronfman Department of Medicine Teaching Excellence, Samuel Bronfman Department of Medicine Grand Rounds Award, Cardiology Fellows Society of Greater New York, The Simon Dack Award, The Jacobi Medallion, The Solomon R. Berson Memorial Award, John R. Murray Award, The University Hospital Chair and the Roland Jackson Memorial Medical Scholarship.

X

Dr. Raymond Wong is Honorary Clinical Associate Professor and Head of the Division of Haematology at the Department of Medicine & Therapeutics of the Chinese University of Hong Kong. He is also Consultant in the Department of Medicine and Therapeutics at the Prince of Wales Hospital, Hong Kong.

Dr. Wong received his medical degree from the Chinese University of Hong Kong and completed his training at Prince of Wales Hospital, Hong Kong in Haematology and Haematological Oncology, Internal Medicine and Clinical Pharmacology and Therapeutics. Dr. Wong undertook his Blood and Marrow Transplantation Fellowship training at the MD Anderson Cancer Center, Texas, USA and gained a Doctor of Medicine at the Chinese University of Hong Kong.

Dr. Wong has broad research interests with a special focus on the biological and therapeutic aspects of leukaemias, autoimmune haematological diseases, stem cell transplantation, bleeding and thrombosis. He served as the Chairman of the Hong Kong Association of Blood Transfusion and Haematology from 2004 to 2005. Dr. Wong is the author or co-author of over 100 peer-reviewed articles, published in international journals such as Blood, Circulation, JAMA and the New England Journal of Medicine.